HERTFORDSHIRE, England and
PITTSBURGH, April 11, 2018 /PRNewswire/ -- Global
pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an
Investor Day, which focuses on the global powerhouse's
differentiation and durability, including its longtime mission to
expand access to medicine, commitment to complex scientific
programs and commercial diversification, and significant financial
flexibility. Additionally, the presentation highlights recently
announced opportunities, including:
- Mylan's acquisition of the global marketing rights to a
once-monthly Glatiramer Acetate product through a partnership with
Mapi Pharma;
- a partnership with Fujifilm Kyowa Kirin Biologics to
commercialize a biosimilar to Humira® (adalimumab) in
Europe (link to
announcement);
- and Mylan's acquisition of the global development and marketing
rights from Prayog Labs for a new, fast-acting formulation of
Meloxicam, a non-opioid pain management option.
Mylan CEO Heather Bresch
commented: "For nearly 60 years, Mylan has remained true to its
core purpose of providing access to medicine. To expand access,
we've built tremendous diversity into our commercial, operational
and scientific platforms. The result is a durable business model
that delivers consistent and reliable results. Today, for example,
we estimate that 75% of the cash flows that Mylan generates are
stable and durable. We look forward to continuing to engage our
many stakeholders about Mylan's unique profile."
Mylan President Rajiv Malik
commented: "We are uniquely positioned to maximize opportunities
for continued growth and commercial differentiation in the global
markets we serve. In parallel, the scientific expertise we have
amassed over the past decade fuels our ability to continue driving
the company's commercial success. To this end, in 2018 we have
dedicated more than half of our R&D investments to complex
product development. Complex products represent about 70% of
Mylan's overall pipeline value, based on IQVIA brand values. These
investments continue to build on our proven ability to develop and
commercialize difficult-to-manufacture products for
patients."
Chief Commercial Officer Tony
Mauro commented: "Mylan has a commercial presence in more
than 165 countries and territories around the world. How we
leverage this reach and expand in these markets drives our
differentiation. Today, for example, more than 60% of Mylan's
revenues come from regions outside of the U.S., including
Europe and Rest of World. As
important, Mylan is poised to outperform market growth in many
ex-U.S. countries over the next five years."
Chief Financial Officer Ken Parks
commented: "We have committed to maintain strong financial
flexibility in support of our business goals, and this disciplined
approach is a key component to the durability of our platform. As
we have continued to diversify our product portfolio and reach
across Mylan's three segments, Mylan has driven strong and
sustainable cash flow generation. In addition to reaffirming our
2018 guidance, we remain committed to deleveraging and maintaining
an investment grade credit rating."
Biosimilars
Mylan's presentation highlights continued
progress on biosimilars across markets and therapeutic areas,
including oncology, diabetes and metabolism, and immunology.
Regarding Mylan's leading portfolio of 16 biosimilar and insulin
analog products on the market or in development worldwide, updates
focus on pipeline products' progression through development, filing
and approval as well as approved products' commercialization
strategy.
Additional Scientific and Product
Highlights
Additional highlights include an overview of
Mylan's advancing respiratory platform, which focus on preparations
for a U.S. generic Advair® launch. Mylan's version,
Wixela™ Inhub™, is expected to come to market during the summer of
2018. The company also notes positive developments in Mylan's
collaboration with 3M to advance
availability of a generic Symbicort® pMDI in the
U.S.
Mylan's investment to expand availability of certain global key
brands, new pipeline opportunities such as conjugated estrogens, a
biosimilar for BOTOX®, and certain healthcare solution services are
also highlighted. Management also discusses growth opportunities
across Mylan's infectious disease franchise and plans to double the
company's over-the-counter, dermatology and injectables
businesses.
Interested parties can access a live webcast of the presentation
via the investor relations section of Mylan's website at
investor.mylan.com. In addition to the webcast, U.S. callers
can access the event, in listen-only mode, at 800.514.4861 or
678.809.2405 for international callers (ID#7597227). A replay
of the webcast also will be available following the live
presentation and can be accessed on the website.
About Mylan
Mylan is a global pharmaceutical company
committed to setting new standards in healthcare. Working together
around the world to provide 7 billion people access to high quality
medicine, we innovate to satisfy unmet needs; make reliability and
service excellence a habit; do what's right, not what's easy; and
impact the future through passionate global leadership. We offer a
growing portfolio of more than 7,500 marketed products around the
world, including antiretroviral therapies on which more than 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
Forward-Looking Statement
This press release
includes statements that constitute "forward-looking statements",
including with regard to: reaffirming 2018 guidance; Mylan
being built to last and positioned for growth; Mylan's acquisition
of the global marketing rights to a once-monthly Glatiramer Acetate
product through a partnership with Mapi Pharma; Mylan's partnership
with Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar
to Humira® (adalimumab) in Europe; Mylan's acquisition of the global
development and marketing rights from Prayog Labs for a new,
fast-acting formulation of Meloxicam, a non-opioid pain management
option; Mylan's durable business model that delivers consistent and
reliable results; Mylan being uniquely positioned to maximize
opportunities for continued growth and commercial differentiation
in the global markets we serve; the scientific expertise we have
amassed over the past decade fueling our ability to continue
driving the company's commercial success; in 2018 we have dedicated
more than half of our R&D investments to complex product
development; complex products representing about 70% of Mylan's
overall pipeline value, based on IQVIA brand values; investments
continue to build on our proven ability to develop and
commercialize difficult-to-manufacture products for patients; Mylan
being poised to outperform market growth in many ex-U.S. countries
over the next five years; that we have committed to maintain strong
financial flexibility in support of our business goals and this
disciplined approach is a key component to the durability of our
platform; that as Mylan continues to diversify our product
portfolio and reach across Mylan's three segments, Mylan has driven
strong and sustainable cash flow generation; in addition to
reaffirming our 2018 guidance, we remain committed to deleveraging
and maintaining an investment grade credit rating; that Mylan's
version, Wixela™ Inhub™, is expected to come to market during the
summer of 2018; positive developments in Mylan's collaboration with
3M to advance availability of a
generic Symbicort® pMDI in the U.S.; Mylan's investment
to expand availability of certain global key brands, new pipeline
opportunities such as conjugated estrogens, a biosimilar for
BOTOX®, and certain healthcare solution services; and growth
opportunities across Mylan's infectious disease franchise and plans
to double the company's over-the-counter, dermatology and
injectables businesses. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: success of clinical trials and our or our
partners' ability to execute on new product opportunities; any
regulatory, legal or other impediments to our or our partners'
ability to bring products to market; other risks inherent in
product development; the scope, timing, and outcome of any ongoing
legal proceedings, including government investigations, and the
impact of any such proceedings on our or our partners' businesses;
actions and decisions of healthcare and pharmaceutical regulators,
and changes in healthcare and pharmaceutical laws and regulations,
in the United States and abroad; the impact of
competition; strategies by competitors or other third parties to
delay or prevent product introductions; the effect of any changes
in our or our partners' customer and supplier relationships and
customer purchasing patterns; any other changes in third-party
relationships; changes in the economic and financial conditions of
the businesses of Mylan or its partners; uncertainties and matters
beyond the control of management; and the other risks detailed in
Mylan's filings with the Securities and Exchange Commission. Mylan
undertakes no obligation to update these statements for revisions
or changes after the date of this release.
View original content with
multimedia:http://www.prnewswire.com/news-releases/investor-day-highlights-durability-of-mylans-global-platform-300628286.html
SOURCE Mylan N.V.